Home > News > Detailed Positive ABRAXANE Phase III Data Released
December 8th, 2003
Detailed Positive ABRAXANE Phase III Data Released
American Pharmaceutical Partners, Inc. and ABRAXIS Oncology, the proprietary drug division of APP, today announced positive results of the randomized, controlled Phase III clinical trial in patients with metastatic breast cancer comparing the investigational product ABRAXANE(TM) to the CremophorŽ solvent-based TAXOLŽ. Patients with metastatic breast cancer receiving the solvent-free nanoparticle paclitaxel, ABRAXANE achieved almost a doubling of the tumor response rate when compared to those patients receiving Bristol-Myers Squibb's TAXOLŽ.
Made-in-Singapore rapid test kit detects dengue antibodies from saliva: IBN's MedTech innovation simplifies diagnosis of infectious diseases January 29th, 2015
Iranian Researchers Planning to Produce Edible Insulin January 28th, 2015
Nanoparticles that deliver oligonucleotide drugs into cells described in Nucleic Acid Therapeutics January 28th, 2015
Nanoliposomes Help Efforts to Cure Bacterial Infections January 27th, 2015